Invesaro

Stocks CLCS Financial statements

Financial statements

Cell Source, Inc. financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Cell Source, Inc. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

FY2015FY2017FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
Research and development0.390.550.640.272.460.831.271.94
Selling, general and administrative1.10.950.821.28
General and administrative1.281.172.642.72.182.61.94
Operating expenses2.322.322.292.013.813.644.024.184.333.84
Operating income-2.29-2.01-3.81-3.64-4.02-4.18-4.33-3.84
Interest expense0.030.240.17-0.220.230.460.63
Other non-operating income-0.181.35-0.79-0.11-0.67-0.92-1.45-0.99-1-0.67
Pre-tax income-3.08-0.97-3.32-2.12-4.48-4.56-5.47-5.17-5.32-4.51
Income tax00000
Income from continuing operations-2.32-2.32-2.29
Net income-2.5-0.97-3.08-2.12-4.48-4.56-5.47-5.17-5.32-4.51
EBITDA-2.29-2.01
EPS, basic-0.10-0.04-0.120.09-0.18-0.19-0.19-0.18-0.17-0.14
EPS, diluted-0.10-0.04-0.120.09-0.18-0.19-0.19-0.18-0.17-0.14
Shares, basic (weighted)25.726.226.827.528.329.133.134.837.841.9
Shares, diluted (weighted)25.726.226.827.528.329.133.134.837.841.9

Balance sheet

FY2015FY2017FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
Cash and equivalents0.0100.370.020.030.240.090.220.020.07
Other current assets0.130.070.040.010.030.030.020.020.010
Total current assets0.210.210.530.450.31
Property, plant and equipment00
Total assets0.210.210.530.070.110.450.310.410.20.29
Accounts payable0.120.220.20.280.140.190.220.681.471.89
Accrued liabilities0.440.880.750.531.051.161.11.49
Total current liabilities5.926.455.094.995.718.410.1
Total liabilities5.976.455.094.995.868.410.11315.818.8
Total debt0.05
Paid-in capital4.725.29.9711.715.417.721.323.72627.6
Retained earnings-10.5-11.5-14.6-16.7-21.1-25.7-31.2-36.3-41.7-46.2
Shareholders' equity-5.76-6.24-4.56-4.92-5.74-7.95-9.83-12.6-15.6-18.5
Total equity-5.76-6.24-4.56-4.92-5.74-7.95-9.83-12.6-15.6-18.5
Total liabilities and equity0.210.210.530.070.110.450.310.410.20.29
Shares outstanding23.924.725.326.127.132.534.436.139.845

Cash flow statement

FY2015FY2017FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
Net income-2.5-0.97-3.08-2.12-4.48-4.56-5.47-5.17-5.32-4.51
Depreciation and amortization0000
Stock-based compensation0.140.110.04-0.020.840.790.420.080.460.29
Deferred income tax-1.54-1.77-0.75-1.48-1.26
Change in payables0.08-0.140.060.030.460.790.42
Cash from operations-2-1.49-2.29-2-2.59-2.77-3.38-3.14-2.35-2.68
Debt issued0.990.120.1
Stock issued0.07
Cash from financing1.991.492.661.652.62.993.233.272.152.74
Net change in cash-0.01-00.37-0.350.010.22-0.150.13-0.20.05
Interest paid0.0200.07
Income taxes paid000.020.020

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to March 31, 2025; growth uses fiscal years. Valuation uses the share price of $0.42 on September 25, 2026.

Profitability

MetricValueHow it is calculated
Return on assets (ROA)-1,614.0%Net income / average total assets.

Growth

MetricValueHow it is calculated
Total assets growth, 1y46.8%Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y-3.0%Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y20.1%Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y10.8%Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y8.1%Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y8.1%Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

MetricValueHow it is calculated
Liabilities / assets6,985.0%Total liabilities / total assets.
Tangible book value-$20.1MShareholders' equity - goodwill - intangible assets.

Per share

MetricValueHow it is calculated
EPS, diluted-$0.10Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share-$0.07Cash from operations / diluted weighted shares.
Book value per share-$0.45Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share-$0.45Tangible book value / shares outstanding.
Cash per share$0.00(Cash + short-term investments) / shares outstanding.

Valuation

MetricValueHow it is calculated
Market cap$28.5MShare price x shares outstanding.
Enterprise value$28.5MMarket cap + total debt - cash - short-term investments.
Earnings yield-16.6%Net income / market cap (the inverse of P/E).
Was Cell Source, Inc. profitable in fiscal 2024?

No. It reported a net loss of $4.5M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to Cell Source, Inc.